Ortho Pharmaceutical
 | This article includes a improve this article by introducing more precise citations. (June 2019) ) |
| Industry | pharmaceutical |
|---|---|
| Founded | 1931 |
| Defunct | 1993 |
| Fate | Merged with Janssen Pharmaceutica in Canada later both became Johnson & Johnson |
Area served | United States |
Ortho Pharmaceutical was initially formed in the United States in 1931 as a subsidiary of Johnson & Johnson to market the first prescription spermicidal contraceptive jelly, Ortho-Gynol.
History
 | This article needs additional citations for verification. (July 2019) |
In the 1940s, Ortho introduced the
diaphragm, and assisted in the development of the Papanicolaou smear stain to screen for cervical cancer
.
In 1963, Ortho introduced the second
RhoGAM Rho(D) immune globulin, the first medication developed to prevent Rh hemolytic disease of the newborn
.
In 1973, Ortho and Syntex introduced the first
progestogen only pills
(mini-pills) available in the United States, Mirconor and Nor-QD.
In 1982, Ortho introduced the first
progestin (norgestimate
) approved in over 20 years in the United States.
In 1992, Ortho introduced Ortho Tri-Cyclen in the United States, which in 1996 became the first oral contraceptive with an FDA-approved non-contraceptive
ParaGard
copper T-380A IUD in the United States.
In 2001, Ortho introduced the Ortho Evra transdermal contraceptive patch in the United States.
In 1993, Ortho Pharmaceutical merged with
McNeil Pharmaceutical in 1993 to form Ortho-McNeil Pharmaceutical
.
In
Janssen Pharmaceutica
Canada in 1995 to form Janssen-Ortho.
See also
- McNeil Laboratories
- Ortho-McNeil Pharmaceutical
- Janssen Pharmaceutica
- Cilag
- Janssen-Cilag
References
- "Ortho: A her-story of achievement in women's health". Women's Health Care. 5 (5): 16–20. 2006.
- "Rh disease and the discovery of RhoGAM: A story with a happy ending". Women's Health Care. 5 (5): 21–26. 2006.
- "Janssen-Ortho, Inc. Our History and Today". 2006. Archived from the original on 2007-12-19. Retrieved 2007-12-08.